Bifogade filer
Xintela Pressrelease 2021-12-13.pdf
Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Xintela announces today that the company has signed a Letter of Intent with the Danish animal health company ScanVet Animal Health A/S. The parties intend to enter into an agreement to develop, market and sell EQSTEM®, Xintela's proprietary equine stem cell product, for the treatment of joint diseases including osteoarthritis.
Under the Letter of Intent, the parties intend to agree on the collaboration structure, the development plan for EQSTEM to market approval, financing, as well as the rights to market and sell EQSTEM in certain European territories. In the intended collaboration, Xintela will manufacture EQSTEM for clinical studies and for commercial sales.
"It is a great opportunity for Xintela to bring EQSTEM to the market together with a partner in the animal health sector which also has a high interest in developing new and effective treatments for horses. ScanVet Animal Health has extensive experience in bringing novel veterinary treatments, including vaccines, to the market and is a leading distributor of animal health products in the Nordics. We very much look forward to continue our discussion with ScanVet Animal health and its CEO Flemming Velin towards a definitive agreement," says Xintela's CEO Evy Lundgren-Åkerlund.
"Xintelas stem cell technology holds great promise for the development of effective treatments for animals. The intended collaboration with Xintela on their equine stem cell product EQSTEM offers ScanVet the opportunity to play a leading role in the development of a competitive stem cell product for the treatment of joint diseases in horses," says Flemming Velin, the CEO of ScanVet Animal Health.
Xintela AB (publ)
Evy Lundgren-Åkerlund, CEO
Tel: +46 46 275 65 00
Email: evy@xintela.se
Medicon Village
223 81 Lund, Sweden
www.xintela.se
This information is such information that Xintela AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08:55 a.m CET on December 13, 2021.
The following documents can be retrieved from beQuoted
Xintela Pressrelease 2021-12-13.pdf
About Xintela
Xintela develops medical products in stem cell therapy and targeted cancer therapy based on the Company's cell surface marker integrin a10b1 which is found on mesenchymal stem cells and on certain aggressive cancer cells. The stem cell marker is used to select and quality-assure the patent-protected stem cell product XSTEM®, which is now entering a clinical development phase for treatment of knee osteoarthritis and difficult-to-heal leg ulcers. The company produces XSTEM for the clinical studies in its GMP-approved manufacturing facility. In cancer therapy, which is run by the wholly owned subsidiary Targinta AB, therapeutic antibodies, targeting integrin a10b1 (First-in-Class) are being developed for the treatment of triple-negative breast cancer and the brain tumor glioblastoma. Xintela conducts its business at Medicon Village in Lund, Sweden, and is listed on Nasdaq First North Growth Market Stockholm since 22 March 2016. Xintela's Certified Adviser at Nasdaq First North Growth Market is Erik Penser Bank AB, +46 8-463 80 00, certifiedadviser@penser.se.
About ScanVet Animal Health A/S
ScanVet Animal Health A/S is a veterinary pharmaceutical company headquartered in Fredensborg, Denmark, that imports and distributes medicines for both companion animals, horses and production animals. The product range is large and includes vaccines, antibiotics, anthelmintics, NSAIDs, hormones, sedatives, analgesics and anesthetics. In addition to prescription drugs, ScanVet also has a product range of feed supplements and care products.